| Year |
Citation |
Score |
| 2019 |
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/Blood.2019000611 |
0.305 |
|
| 2019 |
Cortes JE, Wang ES, Watts JM, Lee S, Baer MR, Dao K, Dinner S, Yang J, Donnellan WB, Schwarer AP, Recher C, Kelly P, Sweeney J, Brevard J, Henrick P, et al. Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine Blood. 134: 674-674. DOI: 10.1182/Blood-2019-124360 |
0.411 |
|
| 2019 |
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner S, Pigneux A, Montesinos P, Wang ES, Seiter K, Wei AH, De Botton S, Arnan Sangerman M, Donnellan WB, ... ... Dao K, et al. Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study Blood. 134: 231-231. DOI: 10.1182/Blood-2019-123920 |
0.397 |
|
| 2019 |
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KW, Zeidan AM, Al-Kali A, Dao K, Deeg HJ, Patel PA, Sabloff M, Keating M, Zhu N, Gabrail NY, Fazal S, Maly J, et al. Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine Blood. 134: 846-846. DOI: 10.1182/Blood-2019-122980 |
0.382 |
|
| 2018 |
Dao K, Collins RH, Cortes JE, Deininger MW, Druker BJ, Gotlib JR, Macey TA, Oh ST, Tyner JW, Winton EF. Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Blood. 132: 350-350. DOI: 10.1182/Blood-2018-99-119476 |
0.444 |
|
| 2018 |
Watts J, Baer MR, Yang J, Dinner S, Lee S, Seiter K, Prebet T, Schiller GJ, Ferrell PB, Dao K, Kantarjian HM, Kelly P, Li P, Sweeney J, Watson C, et al. Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Blood. 132: 1453-1453. DOI: 10.1182/Blood-2018-99-114263 |
0.404 |
|
| 2018 |
Daver NG, Kremyanskaya M, O'Connell C, Dao K, Oh ST, Gerds AT, Verstovsek S, Erickson-Viitanen S, Zhou F, Assad A, Yacoub A. A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis Blood. 132: 353-353. DOI: 10.1182/Blood-2018-99-111338 |
0.36 |
|
| 2017 |
Dao KT, Tyner JW, Gotlib J. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports. PMID 28983816 DOI: 10.1007/S11899-017-0413-Y |
0.338 |
|
| 2016 |
Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Naim A, Svaraman S, Gao J, Gotlib JR, Gupta V, Dao K, Talpaz M, Winton EF, Harvey JH, Verstovsek S. Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study Blood. 128: 1949-1949. DOI: 10.1182/Blood.V128.22.1949.1949 |
0.384 |
|
| 2014 |
Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Pomicter AD, Iovino AJ, Reynolds KR, Eiring AM, Zabriskie MS, Kronenberg Z, Tyner JW, Dalley B, Dao KT, O'Hare T, Yandell M, et al. Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival Blood. 124: 4637-4637. DOI: 10.1182/Blood.V124.21.4637.4637 |
0.312 |
|
| 2013 |
Jiang Q, Crews LA, Barrett CL, Court-Recart A, Goff D, Sadarangani A, Rusert J, Morris S, Goldstein L, Chun H, Marra M, Fraser K, Dao K, Minden M, Jamieson C. Abstract 247: ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Cancer Research. 73: 247-247. DOI: 10.1158/1538-7445.Am2013-247 |
0.328 |
|
| 2011 |
Goff D, Smith KM, Shih AY, Court-Recart A, Sadarangani A, Geron I, Chuang R, Balaian L, Wei J, Kitada S, Zhai D, Gotlib J, Minden MD, Martinelli G, Schairer A, ... ... Dao KT, et al. BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor Blood. 118: 2735-2735. DOI: 10.1182/Blood.V118.21.2735.2735 |
0.335 |
|
| Show low-probability matches. |